Loading...

We've got a brand new version of Simply Wall St! Try it out

Origin House

CNSX:OH
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OH
CNSX
CA$516M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Origin House, formerly known as CannaRoyalty Corp., is a private equity firm specializing in acquisitions. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Origin House is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • Origin House has significant price volatility in the past 3 months.
OH Share Price and Events
7 Day Returns
-10.7%
CNSX:OH
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
5.2%
CNSX:OH
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
OH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Origin House (OH) -10.7% 2.2% -18.9% 5.2% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • OH outperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • OH outperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
OH
Industry
5yr Volatility vs Market

Value

 Is Origin House undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Origin House. This is due to cash flow or dividend data being unavailable. The share price is CA$7.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Origin House's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Origin House's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:OH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.98
CNSX:OH Share Price ** CNSX (2019-09-20) in CAD CA$7.1
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Origin House.

CNSX:OH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:OH Share Price ÷ EPS (both in CAD)

= 7.1 ÷ -0.98

-7.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Origin House is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Origin House is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Origin House's expected growth come at a high price?
Raw Data
CNSX:OH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Origin House, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Origin House's assets?
Raw Data
CNSX:OH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$2.41
CNSX:OH Share Price * CNSX (2019-09-20) in CAD CA$7.1
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:OH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:OH Share Price ÷ Book Value per Share (both in CAD)

= 7.1 ÷ 2.41

2.94x

* Primary Listing of Origin House.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Origin House is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Origin House's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Origin House has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Origin House expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
173%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Origin House expected to grow at an attractive rate?
  • Origin House's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Origin House's earnings growth is expected to exceed the Canada market average.
  • Origin House's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:OH Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:OH Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 173%
CNSX:OH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 96.2%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:OH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:OH Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 280 2
2019-12-31 140 2
2019-09-22
CNSX:OH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 47 -56 -65
2019-03-31 29 -50 -21
2018-12-31 19 -34 -8
2018-09-30 12 -16 -4
2018-06-30 6 -10 0
2018-03-31 3 -8 -11
2017-12-31 3 -9 -9
2017-09-30 3 -9 -15
2017-06-30 2 -8 -13
2017-03-31 1 -6 -12
2016-12-31 1 -5 -12
2016-09-30 0 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Origin House's earnings are expected to grow significantly at over 20% yearly.
  • Origin House's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:OH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Origin House Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OH Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.42 0.42 0.42 1.00
2019-12-31 0.07 0.07 0.07 1.00
2019-09-22
CNSX:OH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.98
2019-03-31 -0.35
2018-12-31 -0.15
2018-09-30 -0.08
2018-06-30 -0.01
2018-03-31 -0.27
2017-12-31 -0.21
2017-09-30 -0.39
2017-06-30 -0.38
2017-03-31 -0.43
2016-12-31 -0.54
2016-09-30 -0.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Origin House will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Origin House's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Origin House has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Origin House performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Origin House's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Origin House does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Origin House's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Origin House's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Origin House's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Origin House Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 47.08 -64.66 53.41 2.63
2019-03-31 29.21 -20.92 41.69 1.81
2018-12-31 18.69 -8.41 30.75 1.10
2018-09-30 11.85 -3.72 22.46 0.39
2018-06-30 5.97 -0.36 16.68 0.46
2018-03-31 3.42 -11.48 13.11 0.53
2017-12-31 3.08 -8.89 11.53 0.93
2017-09-30 2.51 -15.18 10.74 1.32
2017-06-30 1.89 -13.23 10.13 1.21
2017-03-31 0.94 -12.35 8.51 1.22
2016-12-31 0.64 -12.05 7.12 1.26
2016-09-30 0.14 -5.18 3.95 0.90
2016-06-30 0.07 -4.11 2.88 0.89
2016-03-31 -3.03 1.70 0.98
2015-03-31 -0.29 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Origin House has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Origin House has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Origin House improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Origin House's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Origin House has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Origin House's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Origin House's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Origin House's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Origin House's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Origin House's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 19x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Origin House Company Filings, last reported 2 months ago.

CNSX:OH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 162.95 3.01 14.78
2019-03-31 199.59 0.26 39.25
2018-12-31 172.97 16.13 69.21
2018-09-30 147.22 28.01 75.28
2018-06-30 85.24 0.38 15.72
2018-03-31 53.74 3.10 6.06
2017-12-31 40.47 2.68 4.52
2017-09-30 37.43 1.85 2.59
2017-06-30 40.02 1.90 8.36
2017-03-31 40.16 1.89 11.95
2016-12-31 25.48 1.83 2.95
2016-09-30 9.71 1.32 0.31
2016-06-30 1.88 0.44 0.01
2016-03-31 1.88 0.44 0.01
2015-03-31 0.48 0.00 0.49
  • Origin House's level of debt (1.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Origin House's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Origin House has less than a year of cash runway based on current free cash flow.
  • Origin House has less than a year of cash runway if free cash flow continues to grow at historical rates of 89.4% each year.
X
Financial health checks
We assess Origin House's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Origin House has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Origin House's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Origin House dividends.
If you bought CA$2,000 of Origin House shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Origin House's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Origin House's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:OH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:OH Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Origin House has not reported any payouts.
  • Unable to verify if Origin House's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Origin House's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Origin House has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Origin House's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Origin House afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Origin House has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Origin House's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Lustig
COMPENSATION CA$1,177,403
AGE 45
TENURE AS CEO 2.8 years
CEO Bio

Mr. Marc Lustig, MSC, MBA, has been Chief Executive Officer of Origin House since December 5, 2016. He also serves as Chairman at the firm since July, 2018. He has been a Director of Origin House since December 5, 2016. He founded the firm in early 2015. He served as President at the firm since December 5, 2016. He serves as a Director of GMP Securities L.P. at GMP Capital Inc. and 22 Capital Corp. He has been Member of Advisory Board at Elkhorn Gold Mining Corp.(also known as Tidal Royalty Corp.) since June 25, 2018. Mr. Lustig served as a Director at Planet 13 Holdings Incorporation since June 2018 until August 28, 2019. In early 2015, Mr. Lustig founded Cannabis Royalties & Holdings Corp., which is now CannaRoyalty Corp. where he is currently Chief Executive Officer and Director. Mr. Lustig was an Associate of Macquarie Capital Markets Canada Ltd. Mr. Lustig served as Equity Analyst of Macquarie Capital Markets Canada Ltd., Research Division and Macquarie Research. He employed at GMP Securities, Ltd. several years. He worked as a top producer at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming Principal at KES 7 Capital since 2013. Prior to joining GMP Securities, he served as Vice President, Institutional Equity Sales at Orion Securities Inc. in Montreal. He began his professional career in the pharmaceutical industry at Merck & Co. He gained healthcare industry experience working in clinical and management positions at Patheon. In 2000, Mr. Lustig started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities as an associate analyst for the life sciences sector and in 2002, he was promoted to lead the sales/trading effort in the space. He covered a wide range of institutional investors throughout North America, which either participate as part of a general fund or specialize in the healthcare sector. His background provides GMP with a strategic competitive advantage to penetrate accounts with healthcare trading initiatives and to champion healthcare investment banking opportunities through GMP’s Sales and Trading organization. Mr. Lustig holds a Master of Science in Cell Biology and his Master of Business Administration from McGill University.

CEO Compensation
  • Marc's compensation has increased whilst company is loss making.
  • Marc's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Origin House management team in years:

1.7
Average Tenure
51
Average Age
  • The average tenure for the Origin House management team is less than 2 years, this suggests a new team.
Management Team

Marc Lustig

TITLE
CEO & Chairman
COMPENSATION
CA$1M
AGE
45
TENURE
2.8 yrs

Afzal Hasan

TITLE
President & General Counsel
COMPENSATION
CA$850K
TENURE
1.3 yrs

François Perrault

TITLE
Chief Financial Officer
COMPENSATION
CA$634K
AGE
53
TENURE
2.8 yrs

Richard Sellers

TITLE
Vice President of Operations
TENURE
1.7 yrs

Dave Vautrin

TITLE
VP, Sales and Marketing & President of CRBrands
AGE
49

Thomas Finch

TITLE
Director of Corporate Development
TENURE
1.7 yrs

Sadie Reyes

TITLE
President of Continuum
TENURE
1.1 yrs

Todd Marcotte

TITLE
Creative Director
COMPENSATION
CA$195K
AGE
56

Marco Rullo

TITLE
Director of Brand Strategy
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Origin House board of directors in years:

1.5
Average Tenure
64
Average Age
  • The average tenure for the Origin House board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marc Lustig

TITLE
CEO & Chairman
COMPENSATION
CA$1M
AGE
45
TENURE
1.2 yrs

Jim Young

TITLE
Director
COMPENSATION
CA$216K
AGE
66
TENURE
2.8 yrs

Dan O'Neill

TITLE
Director
COMPENSATION
CA$163K
AGE
67
TENURE
1.3 yrs

Rob Harris

TITLE
Director
COMPENSATION
CA$212K
AGE
64
TENURE
2.8 yrs

Oskar Lewnowski

TITLE
Director
COMPENSATION
CA$140K
AGE
53
TENURE
1.8 yrs

Ted Simpkins

TITLE
Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • Origin House individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
03. Jul 19 Sell Afzal Hasan Individual 24. Jun 19 24. Jun 19 -3,000 CA$8.70 CA$-26,100
09. Jan 19 Sell Robert Harris Individual 04. Jan 19 04. Jan 19 -3,800 CA$7.00 CA$-26,600
01. Jan 19 Sell Robert Harris Individual 28. Dec 18 28. Dec 18 -5,000 CA$6.45 CA$-32,250
20. Dec 18 Sell Robert Harris Individual 19. Dec 18 19. Dec 18 -5,000 CA$6.50 CA$-32,500
18. Dec 18 Sell Robert Harris Individual 12. Dec 18 17. Dec 18 -30,000 CA$6.54 CA$-187,207
X
Management checks
We assess Origin House's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Origin House has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Origin House, formerly known as CannaRoyalty Corp., is a private equity firm specializing in acquisitions. The firm invests in the legal cannabis sector with a focus on research and intellectual property, products, consumer brands, and industry infrastructure. It seeks to invest in the United States and Canada. The firm prefers to take majority stake in companies. Origin House is headquartered in Ottawa, Canada.

Details
Name: Origin House
OH
Exchange: CNSX
Founded:
CA$515,839,317
72,653,425
Website: http://www.originhouse.com
Address: Origin House
Preston Square Tower 1,
Suite 610,
Ottawa,
Ontario, K1S 5N4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX OH Common Shares Canadian National Stock Exchange CA CAD 08. Dec 2016
OTCPK ORHO.F Common Shares Pink Sheets LLC US USD 08. Dec 2016
DB CY4 Common Shares Deutsche Boerse AG DE EUR 08. Dec 2016
MUN CY4 Common Shares Boerse Muenchen DE EUR 08. Dec 2016
Number of employees
Current staff
Staff numbers
370
Origin House employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:49
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/09
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.